AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to Severe Plaque Psoriasis

Shots:

• The EC approval is based on four P-III ultIMMa-1, ultIMMa-2, IMMvent & IMMhance assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in 2000+ adult patients with moderate to severe plaque psoriasis
• The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%, 84% & 75%); Skyrizi vs adalimumab, PASI 90 (72% vs 47%); switched patients vs continued adalimumab, PASI 90 (66% vs 21%); @16wks. & 52wks. met its co-1EPs; Skyrizi vs ustekinumab, (DLQI) score (75% & 71% vs 47% & 44%)
• Skyrizi (risankizumab) is a humanized immunoglobulin mAb, inhibits IL-23 by binding to its p19 subunit and has received MHLW’s approval for multiple plaque psoriasis conditions in Mar’19 & Health Canada and the US FDA approval for moderate to severe plaque psoriasis in Apr’19

Click here to read full press release/ article | Ref: AbbVie | Image: The Wall Street Journal